Not recruiting
Bladder transitional cell carcinoma+2
Not recruitingStudy Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer
Registered drugNo placebo
Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer
Registered drugNo placebo
- Disease:Bladder transitional cell carcinomaTransitional cell cancer of the renal pelvis and ureter+1
- Substances:DocetaxelPaclitaxel+2
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Docetaxel
- Sponsor:Gilead Sciences Inc.







